ARES-SERONO FRONE FOR MS SHOWS 67% REDUCTION IN LESIONS AT SIX MONTHS
Executive Summary
ARES-SERONO FRONE FOR MS SHOWS 67% REDUCTION IN LESIONS AT SIX MONTHS in an interim clinical trial Phase II of the company's native human interferon beta for treatment of relapsing-remitting multiple sclerosis. The company announced the results Nov. 4 at the Tenth Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis.